CORT - What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? | Benzinga
Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing’s syndrome (hypercortisolism) in patients with difficult-to-control type 2 diabetes.
Corcept Therapeutics is a pharmaceutical company engaged in discovering, developing, and commercializing drugs for metabolic, psychiatric, and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects.
Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly ...